Work

Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3038

Authors: Scott Kopetz, Rocio Garcia-Carbonero, Sae-Won Han, Ildefonso Ismael Rodriguez Rivera, Jose Carlos Ruffinelli, Valentina Boni, Maria Vieito Villar, Maria J. de Miguel, Athanasios G. Pallis, Christina Habermehl, Abdul Siddiqui, Abhigyan Ravula, Ken Kato

Institutions: The University of Texas MD Anderson Cancer Center, Hospital Universitario 12 De Octubre, Seoul National University, Seoul National University Hospital, Institut Català d'Oncologia, Hospital Universitario Quirónsalud Madrid, IDCQ Hospitales y Sanidad, S.L.U., Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario HM Sanchinarro, Merck Serono S.A.S. (France), Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), EMD Serono, Inc. (United States), National Cancer Center Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410814654

Cites:

Cited by: 2

Related to: 10